Breast cancer early: 100 seconds ENG

GIM

ESMO 2022

Long-term data on dose density therapy in chemotherapy

Nadia Harbeck, MD

Polar

ESMO 2022

Hand cooling and compression both effective in…

Elzbieta Senkus, MD

POLAR

ESMO 2022

Reduction of peripheral neuropathy with taxane therapy

Volkmar Müller, MD

GIM, MONARCH-3, TEAMS, monarchHER, KEYNOTE-522, ADAPT

ESMO 2022

Consolidating data from prospective studies

Michael Untch, MD

ADAPT & ADAPTcycle

ESMO 2022

Endocrine response in eBC

Nadia Harbeck, MD

GIM

ESMO 2022

DD is the champion!

Alessandra Gennari, MD

GIM

ESMO 2022

Dose-dense therapy is beneficial for all patients

Véronique Diéras, MD

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

My highlights of ESMO22

Giuseppe Curigliano, MD

ESMO 2022

Simple and cheap surgical technique may impact survival…

Elzbieta Senkus, MD

BELLINI

ESMO 2022

Immuntherapy only for low risk patients?

Karen Gelmon, MD

GIM

ESMO 2022

Dose-dense standard of care is the optimal care

Karen Gelmon, MD

GIM

ESMO 2022

Dose dense is better

Wolfgang Janni, MD

KEYNOTE-522

ESMO 2022

QoL and longterm toxicity

Diana Lüftner, MD

DATA

ESMO 2022

Roadmap for the adjuvant setting

Hope Rugo, MD

Breast cancer early: 100 seconds Multi Language

Polar

ESMO 2022

Chłodzenie rąk i terapia kompresyjna skutecznie…

Elzbieta Senkus, MD

ESMO 2022

Rosta i tania technika chirurgiczna może wpływać na…

Elzbieta Senkus, MD

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

I miei punti salienti di ESMO22

Giuseppe Curigliano, MD

GIM

ESMO 2022

Il vincitore e’ il dose dense!!

Alessandra Gennari, MD

GIM

ESMO 2022

Schéma dose-dense bénéfique pour toutes les patientes

Véronique Diéras, MD

GIM, MONARCH-3, TEAMS, monarchHER, KEYNOTE-522, ADAPT

ESMO 2022

Datele trialurilor se consolideata

Michael Untch, MD

Breast cancer early: Discussions

KEYNOTE-522, Bellini

ESMO 2022

Status update - adjuvant IO. Are TILs prognostic?

D. Lüftner, V. Diéras, K. Gelmon, N. Harbeck, G. Curigliano, A. Gennari

ESMO 2022

Unmeet needs and my wishes for 2022!

V. Müller, V. Diéras, K. Gelmon, N. Harbeck, G. Curigliano, A. Gennari

ADAPT&ADAPTcylce

ESMO 2022

Who needs Chemo? Who does not? Is OFS plus endocrine…

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

AMEERA, aceLERA

ESMO 2022

How to deal with the negative SERD data?

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

ADAPT&ADAPTcycle, DATA, GIM

ESMO 2022

Tailoring Adjuvant Therapy

V. Müller, V. Diéras, K. Gelmon, N. Harbeck, G. Curigliano, A. Gennari

GIM

ESMO 2022

Dose-dense CT Efficacy confirmed in the Nodal+ ER+…

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

DATA

ESMO 2022

DATA: Still open questions on the optimal duration of…

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

Breast cancer metastatic: 100 seconds ENG

TROPiCS-02

ESMO 2022

Another option for heavily pre-treated HR+ advanced…

Karen Gelmon, MD

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

My highlights of ESMO22

Giuseppe Curigliano, MD

monarcHER

ESMO 2022

CDK4/6i could be an option for selected ER+/HER2+…

Sara Tolaney, MD

TROPiCS-02

ESMO 2022

New treatment option for heavily pre-treated patients…

Véronique Diéras, MD

METEORA-II trial

ESMO 2022

VEX has no place in chemotherapy of metastatic breast…

Diana Lüftner, MD

ELAINE

ESMO 2022

Exciting data, but Phase 3 studies are needed

Karen Gelmon, MD

MONARCH-3

ESMO 2022

Interim analysis shows promising data on Abema in the…

Peter A. Fasching, MD

DAISY

ESMO 2022

Update on biomarkers on ADCs of the DAISY trial

Barbara Pistilli, MD

Ameera

ESMO 2022

Discontinued development

Sara Tolaney, MD

monarcHER

ESMO 2022

HER2+ and still without chemotherapy

Wolfgang Janni, MD

TROPiCS-02

ESMO 2022

Survival benefit from SG in mBC

Volkmar Müller, MD

AMEERA-3, acelERA BC

ESMO 2022

Negative and yet positive?!

Wolfgang Janni, MD

MONARCH-3

ESMO 2022

OS not significant, but re-assuring new data

Véronique Diéras, MD

TROPiCS-02

ESMO 2022

Sacituzumab govitecan for everybody!

Alessandra Gennari, MD

TROPiCS-02

ESMO 2022

New data re-inforces SG as a new option pre-treated…

Hope Rugo, MD

TROPiCS-02

ESMO 2022

ADC after ADC - is there any orientation?

Diana Lüftner, MD

TROPiCS-02

ESMO 2022

TROPiCS-02 highlights

Barbara Pistilli, MD

MONARCH-3

ESMO 2022

The third in the bunch

Wolfgang Janni, MD

MonarcHER

ESMO 2022

Endocrine-based therapy may prove more effective than…

Elzbieta Senkus-Konefka, MD

MONARCH3

ESMO 2022

Survival benefit in endocrine sensitive patients

Alessandra Gennari, MD

monarcHER

ESMO 2022

More therapy options for patients with HR+, HER2+…

Carmen Criscitiello, MD

TROPiCS-02

ESMO 2022

SG is a novel treatment option for HR+/HER2- disease

Carmen Criscitiello, MD

Breast cancer metastatic: 100 seconds Multi Language

MONARCH3

ESMO 2022

Sopravvivenza globale nello studio MONARCH3

Alessandra Gennari, MD

TROPiCS-02

ESMO 2022

Nouvelle option thérapeutique pour les patientes…

Véronique Diéras, MD

TROPiCS-02

ESMO 2022

TROPiCS-02 highlights

Barbara Pistilli, MD

monarcHER

ESMO 2022

Nuove opzioni di trattamento personalizzate per…

Carmen Criscitiello, MD

TROPiCS-02

ESMO 2022

SG come nuova opzione di cura Per pazienti con tumore…

Carmen Criscitiello, MD

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

I miei punti salienti di ESMO22

Giuseppe Curigliano, MD

DAISY

ESMO 2022

Nouvelles données des analyses expolratoires dans…

Barbara Pistilli, MD

MonarcHER

ESMO 2022

Leczenie zaawansowanych raków „potrójnie dodatnich”…

Elzbieta Senkus-Konefka, MD

MONARCH-3

ESMO 2022

Survie globale pas encore significative statistiquement…

Véronique Diéras, MD

TROPiCS-02

ESMO 2022

Sacituzumab Govitecan: Un farmaco per tutte?

Alessandra Gennari, MD

Breast cancer metastatic: Discussions

TROPiCS

ESMO 2022

ADC efficacy in perspective: SG overall survival…

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

MONARCH 3, DAWNA-2, monarcHER

ESMO 2022

Monarch-3: strong OS Survival; DAWNA-2: PFS in line…

M. Untch, R. Dent, H. Rugo, S. Tolaney, B. Pistilli, W. Janni

acelERA BC, AMEERA-3

ESMO 2022

SERDs: equal PFS benefit vs. endocrine therapy;…

W. Janni, S. Tolaney, H. Rugo, R. Dent, B. Pistilli, M. Untch

monacHER

ESMO 2022

CDK4/6i plus Trastuzumab – a possible chemo-free option…

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

TROPiCS-02

ESMO 2022

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd…

W. Janni, H. Rugo, R. Dent, S. Tolaney, B. Pistilli, M. Untch

MONARCH-3

ESMO 2022

Interim OS Data & PFS Update for Abemaciclib hint…

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

NSCLC early stages: 100 seconds ENG

ADAURA

ESMO 2022

ADAURA Update - preventing relapse or just delaying it?

Stephen Liu, MD

INCREASE

ESMO 2022

Concurrent preoperative IO/CRT in early lung cancer

Riyaz Shah, MD

INCREASE

ESMO 2022

Neoadjuvant strategies for PD-L1 < 1 %

Frank Griesinger, MD

ESMO 2022

Pollution and lung cancer - one mechanism revealed

Denis Moro-Sibilot, MD

NeoCOAST

ESMO 2022

Window for treatment selection

Michael Thomas, MD

ADAURA

ESMO 2022

ADAURA revisited

Michael Thomas, MD

ADAURA

ESMO 2022

Osimertinib stays standard adjuvant

Frank Griesinger, MD

ESMO 2022

Liquid biopsy monitoring of EGFR-mutant lung cancer…

Lizza Hendriks, MD

INCREASE

ESMO 2022

INCREASE - to good to be true?

Stephen Liu, MD

INCREASE

ESMO 2022

Double IO + chemoradiotherapy - is it feasible in…

Lizza Hendriks, MD

ADAURA

ESMO 2022

Is OS really needed?

Riyaz Shah, MD

ADAURA

ESMO 2022

Osimertinib - curing or delaying relapse?

Alfredo Addeo, MD

ADAURA

ESMO 2022

Long term follow-up of ADAURA trial

Sacha Rothschild, MD

NSCLC early stages: 100 seconds Multi Language

ADAURA

ESMO 2022

Langzeitdaten ADAURA

Sacha Rothschild, MD

ADAURA

ESMO 2022

Osimertinib bleibt Standard adjuvant

Frank Griesinger, MD

NeoCOAST

ESMO 2022

Eine Plattform für "take the winner"-Strategie

Michael Thomas, MD

ESMO 2022

Pollution et cancer du poumon - un mécanisme mis en…

Denis Moro-Sibilot, MD

ADAURA

ESMO 2022

Osimertinib: una cura o ritarda la ripresa di malattia?

Alfredo Addeo, MD

ADAURA

ESMO 2022

ADAURA revisited

Michael Thomas, MD

INCREASE

ESMO 2022

Dubbele immunotherapie plus chemoradiotherapie - is het…

Lizza Hendriks, MD

ESMO 2022

Liquid biopsie monitoring van patiënten met een EGFR…

Lizza Hendriks, MD

NSCLC early stages - Discussion

ADAURA

ESMO 2022

DFS matters!

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

INCREASE, CheckMate 816

ESMO 2022

Important data on borderline resectable patients

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

NSCLC metastatic: 100 seconds ENG

DICIPLE

ESMO 2022

Can IO be discontinued?

Martin Reck, MD

KEYNOTE-189, KEYNOTE-407

ESMO 2022

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Stephen Liu, MD

CodeBreak 200

ESMO 2022

Sotorasib vs. Docetaxel in mKRAS G12C

Martin Reck, MD

IPSOS

ESMO 2022

New immunotherapy options for pts. ineligible to 1st…

Noemi Reguart, MD

CodeBreaK 200

ESMO 2022

The journey at KRAS G12C continues

Michael Thomas, MD

DICIPLE

ESMO 2022

Duration of immunotherapy : Stop and go strategy for…

Denis Moro-Sibilot, MD

ELIOS, INSIGHT 2

ESMO 2022

If you don't look, vou don't find - once you found it,…

Alfredo Addeo, MD

IPSOS

ESMO 2022

Emerging IO mono options in the first line

Michael Thomas, MD

KEYNOTE-189, KEYNOTE-407

ESMO 2022

5 years of chemoimmunotherapy: solid grounded

Michael Thomas, MD

IPSOS

ESMO 2022

Atezolizumab better than vinorelbin in reduced…

Martin Reck, MD

IPSOS

ESMO 2022

Can we finally treat poor prognostic patients with…

Lizza Hendriks, MD

DICIPLE

ESMO 2022

Question about timing and duration of immunotherapy…

Hossein Borghaei, MD

DESTINY-Lung02

ESMO 2022

HER2 - the next actionable mutation in lung cancer?

Riyaz Shah, MD

CodeBreaK 200

ESMO 2022

Sotorasib: sweet and sour results

Noemi Reguart, MD

KEYNOTE-189, KEYNOTE-407

ESMO 2022

5-year update on 1st line chemoimmunotherapy

Riyaz Shah, MD

CodeBreaK 200

ESMO 2022

One more brick in the KRAS G12C wall

Alfredo Addeo, MD

IPSOS

ESMO 2022

Immunotherapy in unfit population? Perhaps...

Alfredo Addeo, MD

INCREASE

ESMO 2022

Induction chemoimmunotherapy in borderline…

Michael Thomas, MD

DESTINY-Lung02

ESMO 2022

DESTINY-Lung02 - better than the original?

Stephen Liu, MD

CodeBreaK 200

ESMO 2022

A new step in treatment of KRAS G12C mutant NSCLC

Denis Moro-Sibilot, MD

CodeBreaK 200

ESMO 2022

Sotorasib - a new standard of care?

Hossein Borghaei, MD

ESMO 2022

Preview on lung cancer highlights

Nicolas Girard, MD

APPLE

ESMO 2022

Liquid biopsy monitoring in treatment decisions

Frank Griesinger, MD

IMreal

ESMO 2022

Real-world data on Atezolizumab

Nicolas Girard, MD

POSEIDON

ESMO 2022

Poseidon and STK11/KEAP

Michael Thomas, MD

EMPOWER-Lung 1

ESMO 2022

Cemiplimab beyond progression?

Frank Griesinger, MD

KEYNOTE-189, KEYNOTE-407, POSEIDON

ESMO 2022

Chemoimmunotherapy - improvement of survival after 5…

Denis Moro-Sibilot, MD

DESTINY-Lung02

ESMO 2022

Pneumonitis and T-DXd

Michael Thomas, MD

INSIGHT 2

ESMO 2022

New therapy combination after progression on 1L…

Sacha Rothschild, MD

KEYNOTE-189, KEYNOTE-407

ESMO 2022

5-year data on survival under immunotherapy

Sacha Rothschild, MD

DICIPLE

ESMO 2022

Is shorter immunotherapy equally effective and less…

Sacha Rothschild, MD

NSCLC metastatic: 100 seconds Multi Language

APPLE

ESMO 2022

Liquid Biopsy Monitoring zur Therapiesteuerung

Frank Griesinger, MD

EMPOWER-Lung 1

Cemiplimab beyond progression?

Frank Griesinger, MD

IMreal

ESMO 2022

Données de vie réelle avec l’atezolizumab

Nicolas Girard, MD

POSEIDON

ESMO 2022

Poseidon und STK11/KEAP

Michael Thomas, MD

DESTINY-Lung02

ESMO 2022

Pneumonitis und T-DXd

Michael Thomas, MD

CodeBreaK 200

ESMO 2022

Resultados Agridulces de Sotorasib

Noemi Reguart, MD

INSIGHT 2

ESMO 2022

Neue Therapiekombination in der Resistenz nach…

Sacha Rothschild, MD

IPSOS

ESMO 2022

Immunoterapia nella popolazione non fit: forse

Alfredo Addeo, MD

Sacha Rothschild, MD

ESMO 2022

5-Jahresüberleben mit Immuntherapie

Sacha Rothschild, MD

IPSOS

ESMO 2022

Atezo besser als Vino bei PS2-3

Martin Reck, MD

KEYNOTE-189, KEYNOTE-407, POSEIDON

ESMO 2022

Chimio-immunothérapie - amélioration de la survie après…

Denis Moro-Sibilot, MD

ELIOS, INSIGHT 2

ESMO 2022

Se non lo cerchi non lo troiv. Quando lo hai trovato,…

Alfredo Addeo, MD

CodeBreaK 200

ESMO 2022

Une nouvelle étape dans le traitement du CBNPC KRAS…

Denis Moro-Sibilot, MD

INCREASE

ESMO 2022

IO-IO neoadjuvant bei PD-L1 neg.

Frank Griesinger, MD

CodeBreaK 200

ESMO 2022

Die Reise bei KRAS G12C geht weiter

Michael Thomas, MD

IPSOS

ESMO 2022

Neue Option der IO-Therapie in der Erstlinie

Michael Thomas, MD

INCREASE

ESMO 2022

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Michael Thomas, MD

DICIPLE

ESMO 2022

Kann IO pausiert werden?

Martin Reck, MD

CodeBreaK 200

ESMO 2022

Un mattone in piu' nel muro del KRAS G12C

Alfredo Addeo, MD

IPSOS

ESMO 2022

Kunnen we eindelijk patiënten met een slechte prognose…

Lizza Hendriks, MD

DICIPLE

ESMO 2022

Durée de l'immunothérapie : stratégie Stop and Go pour…

Denis Moro-Sibilot, MD

IPSOS

ESMO 2022

Una nueva opción de tratamiento con IO en pacientes no…

Noemi Reguart, MD

ESMO 2022

Les études incontournables à l’ESMO 2022

Nicolas Girard, MD

DICIPLE

ESMO 2022

Kürzere Immuntherapie gleich effektiv aber weniger…

Sacha Rothschild, MD

CodeBreak 200

ESMO 2022

Sotorasib vs. Docetaxel bei mKRAS G12C

Martin Reck, MD

Keynote-189, KEYNOTE-407

ESMO 2022

5 Jahre Chemo-Immuntherapie: starker Effekt

Michael Thomas, MD

NSCLC metastatic - Discussions

DICIPLE, IPSOS

ESMO 2022

New strategies in immunotherapy

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

CodeBreaK 200

ESMO 2022

A positive study! With a question mark?

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

APPLE, ELIOS, INSIGHT 2

ESMO 2022

Heterogenity in the genetic landscape - little progress…

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

EMPOWER-Lung 1, KEYNOTE-189, KEYNOTE-407

ESMO 2022

Novel data and long-term efficacy of chemo-IO in mNSCLC

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

Kidney cancer: 100 seconds ENG

IMmotion101, Checkmate 914, PROSPER

ESMO 2022

Immune-based peri-operative treatment in RCC: What went…

Ignacio Duran, MD

COSMIC-313

ESMO 2022

New combo - triplet therapy for kidney cancer

Joaquim Bellmunt, MD

PROSPER

ESMO 2022

More questions being raised

Thomas Powles, MD

CheckMate914

ESMO 2022

No value of IPI/Nivo in the adjuvant setting.

Axel S. Merseburger, MD

IMmotion010, CheckMate 914

ESMO 2022

News in terms of adjuvant

Philipp Ivanyi, MD

COSMIC-313

ESMO 2022

Exciting data for high-risk patients: is this the start…

P. Goebell, P. Ivanyi

CheckMate914; IMmotion101

ESMO22

Two negative studies question adjuvant approach in RCC

Tom Powles, MD

CheckMate914, IMmotion101, PROSPER

ESMO 2022

Adjuvant Immuntherapy in kidney cancer

Joaquim Bellmunt, MD

CheckMate914, IMmotion101, PROSPER, COSMIC-313, and more

ESMO 2022

Brief highlights about RCC & urothelial cancer from…

Petros Grivas, MD

IMmotion010, CheckMate 914

ESMO 2022

Adjuvant CPI in kidney cancer – 2 phase III trials with…

Philipp Ivanyi, MD

COSMIC-313

ESMO 2022

Place of triplet therapy

Axel S. Merseburger, MD

Kidney cancer: 100 seconds Multi Language

COSMIC-313

ESMO 2022

Terapia triple para cancer renales

Joaquim Bellmunt, MD

CheckMate914, IMmotion101, PROSPER, COSMIC-313

ESMO 2022

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Petros Grivas, MD

CheckMate914, IMmotion101, PROSPER

ESMO 2022

Inmunoterapia adyuvante en el cancer renales

Joaquim Bellmunt, MD

IMmotion101, Checkmate 914, PROSPER

ESMO 2022

Tratamiento perioperatorio con immunoterapia en cáncer…

Ignacio Duran, MD

Kidney cancer: Discussions

PIVOT-09

ESMO 2022

Immunomodulation in combination with…

P. J. Goebell, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

CLEAR, KEYNOTE-B61

ESMO 2022

Shedding light on TKI/Checkpointinhibitor combinations

P. J. Goebell, M.-O. Grimm, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

CheckMate914, IMmotion101, PROSPER

ESO 2022

Adjuvant immunotherapy options in RCC - what do we…

P. J. Goebell, M.-O. Grimm, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

COSMIC-313, TITAN-RCC

ESMO 2022

Therapy combinations in RCC - what is the role of…

P. J. Goebell, M.-O. Grimm, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

Bladder cancer: 100 seconds ENG

LBA73

ESMO 2022

EV + pembrolizumab in cisplatin-ineligible patients

Axel S. Merseburger, MD

CheckMate914, IMmotion101, PROSPER, COSMIC-313, and more

ESMO 2022

Brief highlights about RCC & urothelial cancer from…

Petros Grivas, MD

EV-103 Cohort K

ESMO 2022

EV + Pembro with excellent response rates

Thomas Powles, MD

Bladder cancer: 100 seconds Multi Language

EV-103, JAVELIN-Bladder100, IMvigor130

ESMO 2022

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Petros Grivas, MD

Bladder cancer: Discussions

JAVELIN-Bladder100, IMvigor130

ESMO 2022

Biomarker exploration in urothelial cancer - finding…

M.-O. Grimm, P. Grivas, T. Powles, J. Bellmunt

RACE IT

ESMO 2022

Adjuvant and neoadjuvant therapy approaches in…

L. Krabbe, P. Grivas, T. Powles, J. Bellmunt

EV-103

ESMO 2022

Promising data, but beware of toxicity

L. Krabbe, P. Grivas, T. Powles, J. Bellmunt, M.-O. Grimm

Prostate cancer: 100 seconds ENG

P1/2a study of PRL-02

ESMO 2022

IM arbiraterone decanoate might demonstrate superior…

Neal Shore, MD

ENACT

ESMO 2022

Biomarker data for better patients selection

Neal Shore, MD

RADICALS-HD

ESMO 2022

Length of hormone therapy after radiation

Axel S. Merseburger, MD

ARASENS

ESMO 2022

Triplet therapy with darolutamide in prostate cancer

Mar-Oliver Grimm, MD; Laura-Maria Krabbe, MD

PRESTO

ESMO 2022

Should intensification of ADT be considered in…

Gil Morgan, MD

KEYLYNK-010

ESMO 2022

IO + PARP without benefit in the allcomer situation

Axel S. Merseburger, MD

PROpel

ESMO 2022

Genetic testing before PARP therapy is useful

Axel S. Merseburger, MD

ARCHES

ESMO 2022

ADT + ENZA better choice than monotherapy

Neal Shore, MD

ARASENS

ESMO 2022

QoL data from ARASENS triplet therapy study mHRPC

Anders Bjartell, MD

PROpel

ESMO 2022

Update on the PROpel study

Anders Bjartell, MD

ESMO 2022

Cabazitaxel better tolerated in elderly men

Axel S. Merseburger, MD

ESMO 2022

ADCs - a possible therapeutic approach

Axel S. Merseburger, MD

PROpel

ESMO 2022

Combination of olaparib leads to promising results

Gil Morgan, MD

CABASTY

ESMO 2022

In older vulnerable - less is more

Gil Morgan, MD

RADICALS HD

ESMO 2022

Radicals - ADT & Radiotherapy

Gil Morgan, MD

CABASTY

ESMO 2022

Optimizing cabazitaxel chemotherapy

Marc-Oliver Grimm, MD; Laura-Maria Krabbe, MD

VISION

ESMO 2022

Further evaluation of PSA correlates

Neal Shore, MD

PEACE-1

ESMO 2022

PSA at 8-months as a biomarker

Anders Bjartell, MD

Prostate cancer: 100 seconds Multi Language

PEACE-1

ESMO 2022

PSA efter 8 månader i PEACE-1 studien som biomarkör

Anders Bjartell, MD

PROpel

ESMO 2022

Uppdatering i PROpel studien

Anders Bjartell, MD

ARASENS

ESMO 2022

Livskvalitetsuppföljning i ARASENS studien

Anders Bjartell, MD

Prostate cancer: Discussions

ESMO 2022

E. Efstathiou, M-O. Grimm, L. Krabbe, Y. Loriot, G. Morgan

Practice changing data - only for older and more…

CABASTY

ESMO 2022

A. Merseburger, E. Efstathiou, N. Shore, D. Murphy, Y. Loriot

Positive results, but testing not that simple

STAMPEDE, PROpel

ESMO 2022

A. Bjartell, Y. Loriot, A. Merseburger, G. Morgan, D. Murphy, N. Shore

Modern Imaging is the new standard

PRESTO

ESMO 2022

A. Bjartell, L. Krabbe, Y. Loriot, A. Merseburger, D. Murphy,

Which men benefit from adding ADT?

RADICAL

ESMO 2022

M-O Grimm, A. Bjartell, Y. Loriot, E. Efstathiou, G. Morgan, D. Murphy

PSA response after triplet therapy: What is the impact…

PEACE-1, ARASENS

Varia

ESMO 2022

Intimate partner violence in cancer patients

Riyaz Shah, MD

BNT211-01

ESMO 2022

Novel approach von Biontech towards Cancer – game…

Philipp Ivanyi, MD

DeFi

ESMO 2022

New group of substances for rare diseases

Philipp Ivanyi, MD

ESMO2 022

IAP-inhibition – comming game changer in LA-HNSCC…

Philipp Ivanyi, MD

KEYNOTE-412

ESMO 2022

Addition of CPI to Radiochemotherapy in LA-HNSCC?

Philipp Ivanyi, MD

ESMO 2022

TILs - Fashion is the eternal return of the old

Philipp Ivanyi, MD